EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy

Alexandre Bouzemane, Emmanuelle Vignot, Laurence Derain Dubourg, Aurélie De Mul, Arnaud Molin, Roland Chapurlat, Elisabeth Fontanges, Daphne Delsart, Alireza Akbari, Shih Han Susan Huang, Christopher W McIntyre, Justine Bacchetta und 1 weitere

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad608 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Alexandre Bouzemane und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hospices Civils de Lyon, Nephrology, hypertension renal and functional exploration, Hôpital Edouard Herriot, 69003, Lyon, France. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Cardiovascular Diseases, Hypertension, Hypophosphatemia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

X-linked hypophosphatemia (XLH) is a rare genetic disorder that results in increased plasma levels of fibroblast growth factor 23 (FGF23). Several studies have demonstrated a direct association between FGF23 and cardiovascular mortality in cohorts of patients with chronic renal failure. However, in patients with XLH, studies on the cardiovascular impact of the disease are rare, with contradictory results.

Objective

The aim was to assess whether the disease led to an increased cardiovascular risk.

Methods

We conducted a single-center retrospective observational study on a local cohort of adult patients with XLH. The primary endpoint was a composite endpoint of the frequency of left ventricular hypertrophy (LVH) or presence of high blood pressure. Our secondary objectives were to assess echocardiographic, pulse wave velocity, and central blood pressure data as other markers of CV health. Independently of this cohort, tissue sodium content with magnetic resonance imaging was studied in 2 patients with XLH before and after burosumab.

Results

Twenty-two patients were included. Median serum phosphate was 0.57 (0.47-0.72) mmol/L and FGF23 94 pg/L (58-2226). Median blood pressure was 124 (115-130)/68 (65-80) mm Hg, with only 9% of patients being hypertensive. A majority of patients (69%) had no LVH, only 1 had a left ventricular mass >100 g/m² and 25% of patients had left ventricular remodeling. Pulse wave velocity was normal in all patients. No differences in skin and muscle sodium content were observed before and after burosumab in the 2 patients who underwent sodium magnetic resonance imaging.

Conclusion

We found no elevated risk of developing hypertension or LVH in patients with XLH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Familial Hypophosphatemic RicketsCardiovascular DiseasesHypertensionHypophosphatemiaAdultHumansPulse Wave AnalysisRisk FactorsHypertrophy, Left VentricularHeart Disease Risk FactorsSodiumFibroblast Growth FactorsPhosphates

Stichwörter der Autor:innen

MRIX-linked hypophosphatemia (XLH)cardiovascular outcomessodium

Substanzen

SodiumFibroblast Growth FactorsPhosphates

Autor:innen und Institutionen

  • Hospices Civils de Lyon, Nephrology, hypertension renal and functional exploration, Hôpital Edouard Herriot, 69003, Lyon, France.
  • Rheumatology Department, CHU Edouard-Herriot, 69003 Lyon, France.
  • Reference centre for rare calcium and phosphorus diseases, paediatric rheumatology and dermatology, rare diseases network, OSCAR, ORKID, ERKNet BOND, HFME, Bron 69029, France.
  • Genetic department, Centre Hospitalier Universitaire de Caen, Caen, 14033, France.
  • Cardiology functional explorations, Hopital Edouard-Herriot, 69003 Lyon, France.
  • Canada Kidney clinical research unit, London Health Sciences Centre, East London, ON, N6A 5W9Canada.

ORCID-Profile: Sandrine Lemoine

Zitieren

APA

Bouzemane, A., Vignot, E., Derain Dubourg, L., De Mul, A., Molin, A., Chapurlat, R., Fontanges, E., Delsart, D., Akbari, A., Huang, S. H. S., McIntyre, C. W., Bacchetta, J., & Lemoine, S. (2024). Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad608

Vancouver

Bouzemane A, Vignot E, Derain Dubourg L, De Mul A, Molin A, Chapurlat R, et al. Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad608

BibTeX
@article{Bouzemane2024,
  author = {Bouzemane, Alexandre and Vignot, Emmanuelle and Derain Dubourg, Laurence and De Mul, Aurélie and Molin, Arnaud and Chapurlat, Roland and Fontanges, Elisabeth and Delsart, Daphne and Akbari, Alireza and Huang, Shih Han Susan and McIntyre, Christopher W and Bacchetta, Justine and Lemoine, Sandrine},
  title = {Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad608}
}
Kostenlos starten →